These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 35957693)

  • 1. Leucine zipper downregulated in cancer 1 may serve as a favorable prognostic biomarker by influencing proliferation, colony formation, cell cycle, apoptosis, and migration ability in hepatocellular carcinoma.
    Chen H; Chen S; Chen C; Li A; Wei Z
    Front Genet; 2022; 13():900951. PubMed ID: 35957693
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of LDOC1 on colorectal cancer cells via downregulation of the Wnt/β-catenin signaling pathway.
    Jiang J; Li Y; Jiang Z
    Oncol Rep; 2019 Jun; 41(6):3281-3291. PubMed ID: 31002361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogene PLCE1 may be a diagnostic biomarker and prognostic biomarker by influencing cell cycle, proliferation, migration, and invasion ability in hepatocellular carcinoma cell lines.
    Wang XK; Liao XW; Yang CK; Liu ZQ; Han QF; Zhou X; Zhang LB; Deng T; Gong YZ; Huang JL; Huang R; Han CY; Yu TD; Su H; Ye XP; Peng T; Zhu GZ
    J Cell Physiol; 2020 Oct; 235(10):7003-7017. PubMed ID: 32037547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LDOC1 inhibits proliferation and promotes apoptosis by repressing NF-κB activation in papillary thyroid carcinoma.
    Zhao S; Wang Q; Li Z; Ma X; Wu L; Ji H; Qin G
    J Exp Clin Cancer Res; 2015 Dec; 34():146. PubMed ID: 26637328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of cancer susceptibility candidate 2 inhibited progression of hepatocellular carcinoma cells.
    Gao X; Du H; Zhang R; Li C; Wang H; Xuan Q; Liu D
    J Cell Physiol; 2019 Jun; 234(6):9008-9018. PubMed ID: 30362539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of PI3K/AKT is involved in TINAG-mediated promotion of proliferation, invasion and migration of hepatocellular carcinoma.
    Zhang MH; Niu H; Li Z; Huo RT; Wang JM; Liu J
    Cancer Biomark; 2018; 23(1):33-43. PubMed ID: 29991125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LDOC1 as Negative Prognostic Marker for Vulvar Cancer Patients.
    Wanka G; Schmoeckel E; Mayr D; Fuerst S; Kuhn C; Mahner S; Knabl J; Karsten MM; Dannecker C; Heidegger HH; Vattai A; Jeschke U; Jueckstock J
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CCT4 suppression inhibits tumor growth in hepatocellular carcinoma by interacting with Cdc20.
    Li F; Liu CS; Wu P; Ling AS; Pan Q; Li XN
    Chin Med J (Engl); 2021 Nov; 134(22):2721-2729. PubMed ID: 34732665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CPNE1 is a potential prognostic biomarker, associated with immune infiltrates and promotes progression of hepatocellular carcinoma.
    Su J; Huang Y; Wang Y; Li R; Deng W; Zhang H; Xiong H
    Cancer Cell Int; 2022 Feb; 22(1):67. PubMed ID: 35139863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LDOC1 regulates Wnt5a expression and osteosarcoma cell metastasis and is correlated with the survival of osteosarcoma patients.
    Yong BC; Lu JC; Xie XB; Su Q; Tan PX; Tang QL; Wang J; Huang G; Han J; Xu HW; Shen JN
    Tumour Biol; 2017 Feb; 39(2):1010428317691188. PubMed ID: 28240050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell division cycle associated 8: A novel diagnostic and prognostic biomarker for hepatocellular carcinoma.
    Cui XH; Peng QJ; Li RZ; Lyu XJ; Zhu CF; Qin XH
    J Cell Mol Med; 2021 Dec; 25(24):11097-11112. PubMed ID: 34741389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lecithin-cholesterol acyltransferase is a potential tumor suppressor and predictive marker for hepatocellular carcinoma metastasis.
    Li Y; Jiang LN; Zhao BK; Li ML; Jiang YY; Liu YS; Liu SH; Zhu L; Ye X; Zhao JM
    World J Gastrointest Oncol; 2024 Aug; 16(8):3651-3671. PubMed ID: 39171187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of LDOC1 in human biliary epithelial cells inhibits apoptosis through NF-κB signaling.
    Song Z; Dong R; Zhao R; Zheng S
    J Pediatr Gastroenterol Nutr; 2013 Dec; 57(6):713-7. PubMed ID: 23942005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic silencing of the LDOC1 tumor suppressor gene in ovarian cancer cells.
    Buchholtz ML; Brüning A; Mylonas I; Jückstock J
    Arch Gynecol Obstet; 2014 Jul; 290(1):149-54. PubMed ID: 24554348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Down-Regulated NRSN2 Promotes Cell Proliferation and Survival Through PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma.
    Wang X; Han L; Zhang J; Xia Q
    Dig Dis Sci; 2015 Oct; 60(10):3011-8. PubMed ID: 26055238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of lncRNA OGFRP1 inhibits hepatocellular carcinoma progression by AKT/mTOR and Wnt/β-catenin signaling pathways.
    Chen W; You J; Zheng Q; Zhu YY
    Cancer Manag Res; 2018; 10():1817-1826. PubMed ID: 29997441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LDOC1 is differentially expressed in thyroid cancer and display tumor-suppressive function in papillary thyroid carcinoma.
    Zhao S; Zhao Y; Wang Q; Li Z; Ma X; Wu L; Li W; Du M; Ji H; Qin G
    Cell Biol Int; 2020 Apr; 44(4):985-997. PubMed ID: 31889386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aloperine induces apoptosis and G2/M cell cycle arrest in hepatocellular carcinoma cells through the PI3K/Akt signaling pathway.
    Liu JS; Huo CY; Cao HH; Fan CL; Hu JY; Deng LJ; Lu ZB; Yang HY; Yu LZ; Mo ZX; Yu ZL
    Phytomedicine; 2019 Aug; 61():152843. PubMed ID: 31039533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. STYXL1 promotes malignant progression of hepatocellular carcinoma via downregulating CELF2 through the PI3K/Akt pathway.
    Wu JZ; Jiang N; Lin JM; Liu X
    Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):2977-2985. PubMed ID: 32271415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Centromere protein N may be a novel malignant prognostic biomarker for hepatocellular carcinoma.
    Wang Q; Yu X; Zheng Z; Chen F; Yang N; Zhou Y
    PeerJ; 2021; 9():e11342. PubMed ID: 33987018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.